Relationship between dyslipidemia and diabetic retinopathy in type II diabetic patients: A case-control study in Peru
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.162.1844Keywords:
Diabetic retinopathy, dyslipidemias, risk factors, case-control studiesAbstract
Background: Diabetic retinopathy (DR) is a primarily asymptomatic microvascular complication. Even though it is preventable, it is the first cause of irreversible blindness among working-age adults. Due to recent meta-analysis results, dyslipidemia is an inconclusive risk factor; therefore, the importance of accomplishing our study in the Peruvian population. Objective: Evaluate the relationship between dyslipidemia and DR in type II diabetic patients of the Ophthalmology area from the Edgardo Rebagliati Martins National Hospital in Lima-Peru, from 2018 to 2020. Methods: Case-control study, 219 cases and 219 controls were included. Diabetic patients will be classified based on the presence or absence of DR lesions on the ocular fundus determined by the specialist. Lipids parameters (triglyceride, LDL, HDL, total cholesterol) and other variables were recollected and analyzed in STATA 14. Multivariate logistic regression was used to obtain a crude and adjusted Odds Ratio. Results: Dyslipidemia (OR 2.7, p=0.03), elevated triglycerides (OR 1.0044, p=0.03), and low HDL cholesterol (OR 2.16, p=0.03) were significantly associated with DR. Conclusion: Dyslipidemia is an independent risk factor for DR in type II diabetic patients. This result emphasizes the importance of evaluating a lipid panel in diabetic patients.
Downloads
Metrics
References
International Diabetes Federation. IDF Diabetes Atlas. 9th Edition, Brussels; 2019. Disponible en: https://diabetesatlas.or
Carrera Boada C. A., Martínez-Moreno J. M. Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit". Nutr. Hosp. 2013 Mar; 28(Suppl 2): 78-87. doi: 10.3305/nh.2013.28.sup2.6717.
Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–31. doi: 10.4103/0301-4738.100542.
Adrianzén RE, Rioja M, Manrique A. Frequency and severity of diabetic retinopathy in patients with type 2 diabetes mellitus at the regional institute of ophthalmology. Rev Peru Med Exp Salud Publica. 2019;36(2):260–4. doi: 10.17843/rpmesp.2019.362.4076.
Asociación Panamericana de Oftalmología . Actualización de la Guía Clínica de Retinopatía Diabética para Latinoamérica. 2016. Disponible en: https://paao.org/
EsSalud. Guía de práctica clínica para el diagnóstico y tratamiento de la retinopatía diabética y el edema macular diabético. Guía en versión extensa [Internet]. 2019 [Citado el 1 de diciembre del 2020]. p. 1–38. Disponible en: http://www.essalud.gob.pe/ietsi/pdfs/tecnologias_sanitarias/GPC_RD_y_EMD_Vers_Extensa.pdf
Organización Mundial de la Salud. Ceguera y discapacidad visual [Internet]. 2021. [Citado el 18 de junio del 2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/blindness-and-visual-impairment
American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care [Internet]. 2022; 25 (suppl_1): s28–s32. Disponible en: https://doi.org/10.2337/diacare.25.2007.S28
Revilla L. Situación epidemiológica de la diabetes al I semestre de 2018. Boletín Epidemiológico del Perú. [Internet]. Vol. 27, Boletín Epidemiológico del Perú; 2018 [Citado el 24 de noviembre de 2020] p. 837–40. Disponible en: https://www.dge.gob.pe/portal/docs/vigilancia/boletines/2018/36.pdf
Zhou Y, Wang C, Shi K, Yin X. Relationship between dyslipidemia and diabetic retinopathy: A systematic review and meta-analysis. Medicine (Baltimore) [Internet]. 2018 Sep [Citado el 13 de octubre de 2020];97(36): e12283. doi: 10.1097/MD.0000000000012283.
Lima VC, Cavalieri GC, Lima MC, Nazario NO, Lima GC. Risk factors for diabetic retinopathy: A case-control study. Int J Retin Vitr [Internet]. 2016 Dec 12 [Citado el 1 de septiembre de 2020];2(1):21. doi: 10.1186/s40942-016-0047-6.
Ministerio de Salud. Guía técnica: Guía de práctica clínica para el diagnóstico, manejo y control de dislipidemia, complicaciones renales y oculares en personas con diabetes mellitus tipo 2 [Internet]. 2017 [Citado el 16 de octubre de 2020]. Disponible en: http://bvs.minsa.gob.pe/local/MINSA/4186.pdf
Chaveepojnkamjorn W, Somjit P, Rattanamongkolgul S, Siri S, Pichainarong N. Factors associated with diabetic retinopathy among type 2 diabetic patients: A hospital based case-control study. Southeast Asian J Trop Med Public Health. 2015;46(2):322–9.
Penman A, Hancock H, Papavasileiou E, James M, Idowu O, Riche DM, et al. Risk factors for proliferative diabetic retinopathy in African Americans with type 2 diabetes. Ophthalmic Epidemiol. 2016;23(2):88–93. doi: 10.3109/09286586.2015.1119287.
Martín-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia-Rodriguez L. Risk factors for diabetic retinopathy in people with Type 2 diabetes: A case–control study in a UK primary care setting. Prim Care Diabetes. 2016 Aug; 10(4):300-8. doi: 10.1016/j.pcd.2016.01.002.
Hammer SS, Busik JV. The role of dyslipidemia in diabetic retinopathy. HHS Public Access; 2017 Oct; 139:228-36. doi: 10.1016/j.visres.2017.04.010.
Srinivasan S, Raman R, Dnb MS, Kulothungan V, Sharma T, et al. Influence of serum lipids on the incidence and progression of diabetic retinopathy and macular oedema Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN DREAMS II). Clin Exp Ophthalmol. 2017 Dic, 45(9): 894-900. doi: https://doi.org/10.1111/ceo.12990.
Instituto de Evaluación de Tecnologías en Salud e Investigación. Resolución del Instituto de Evaluación de Tecnologías en Salud e Investigación Nº150-IETSI-ESSALUD-2019 [Internet]. Lima; 2019 [Citado el 12 de agosto de 2020]. Disponible en: http://www.essalud.gob.pe/ietsi/pdfs/direcc_invest_salud/Resolucion_150_IETSI_ESSALUD_2019.pdf
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Milssa Paucar-Huamani, Karla Abado, Nilton Yhuri Carreazo, Milssa Huamani-Leandro
This work is licensed under a Creative Commons Attribution 4.0 International License.
